Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Cardiopulmonary resuscitation with balloon occlusion of the descending aorta for hospitalized patients

Official title: CPReboa: In-hospital Cardiopulmonary Resuscitation With Balloon Occlusion of the Descending Aorta

Run by Insel Gruppe AG, University Hospital Bern · NCT07434726 · Data updated 2026-11-12

This trial will test whether adding a balloon occlusion of the descending aorta (REBOA) to standard ACLS helps people having an in-hospital cardiac arrest regain and keep a pulse.

More Cardiac Arrest trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment98 (estimated)
SponsorInsel Gruppe AG, University Hospital Bern
Academic / other
Locations1 site (Bern)
StatusRecruiting
StartedApril 14, 2026
Main results expectedDecember 2030
Study endsDecember 2030
Registry record updatedAugust 21, 2026
Trial IDNCT07434726 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adult patients with ongoing in-hospital cardiac arrest (including those who re-arrest after OHCA in the ED) who have any electrical cardiac activity on initial rhythm analysis and in whom femoral arterial access can be achieved while resuscitation continues.

Probably not a fit

Patients with asystole on initial rhythm, traumatic arrest, known DNR orders, pregnancy, prohibitive aortic pathology, or inability to obtain femoral access are unlikely to benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults who have an in-hospital cardiac arrest outside the operating room, ICU, or cath lab and who meet inclusion criteria will be randomized during active resuscitation to receive standard advanced cardiac life support (ACLS) alone or ACLS plus placement of a REBOA catheter to occlude the descending thoracic aorta. A research team deploys simultaneously with the clinical resuscitation team, and femoral artery access must be obtained to allow randomization. The primary focus is frequency of sustained return of spontaneous circulation (ROSC); secondary care, imaging contrast risks, and exclusion criteria such as asystole, pregnancy, known DNR, traumatic arrest, or prohibitive aortic pathology are pre-specified. The intervention is performed in-hospital with immediate monitoring and standard post-ROSC care.

Why it matters

Potential benefit: If successful, adding REBOA could increase the chances of sustained return of circulation during in-hospital cardiac arrest and potentially improve survival and neurologic outcomes.

How similar studies have gone: REBOA has shown benefit in traumatic hemorrhage and some animal and small human studies suggest it can raise coronary perfusion during CPR, but randomized human data for nontraumatic cardiac arrest is limited and this application is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion criteria:

* patients suffering from in hospital cardiac arrest (IHCA), including patients with out of hospital cardiac arrest (OHCA) and return of spontaneous circulation (ROSC), transported to the emergency department, where they suffer a second arrest (IHCA)
* successful placement of a femoral artery introducer sheath
* any electrical cardiac activity seen in the initial rhythm analysis
* ongoing effort of resuscitation as determined by study-independent resuscitation lead

Exclusion criteria:

* IHCA in the operating room, on intensive care unit or in the cardiac catheter laboratory
* hospital visitors suffering from cardiac arrest
* asystole seen in the initial rhythm analysis
* (presumed) age under 18 years
* known "do not resuscitate"-order
* known or obvious pregnancy
* traumatic cardiac arrest
* known aortic pathologies that render cannulation impossible
* known allergies to radiographic contrast agents

Where it's running

  • Inselspital University Hospital Bern
    Bern, Switzerland
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.